BCAX (Bicara Therapeutics) PB Ratio: 3.62 (As of Jun. 29, 2026)


BCAX Bicara Therapeutics Inc BCAX
12 GF Score
Price $28.37
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics PB Ratio?

Bicara Therapeutics BCAX +5.58% 12 PB Ratio is 3.62 as of Jun. 29, 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,232 Biotechnology companies, Bicara Therapeutics ranks worse than 57.71% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-29), Bicara Therapeutics's share price is $28.37. Bicara Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $7.84. Hence, Bicara Therapeutics's PB Ratio of today is 3.62.

The historical rank and industry rank for Bicara Therapeutics's PB Ratio or its related term are showing as below:

BCAX' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 3.63
Current: 3.62

During the past 4 years, Bicara Therapeutics's highest PB Ratio was 3.63. The lowest was 0.00. And the median was 0.00.

BCAX's PB Ratio is ranked worse than
57.71% of 1232 companies
in the Biotechnology industry
Industry Median: 2.835 vs BCAX: 3.62

During the past 12 months, Bicara Therapeutics's average Book Value Per Share Growth Rate was -21.50% per year.

Back to Basics: PB Ratio


Bicara Therapeutics  (NAS:BCAX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Bicara Therapeutics PB Ratio Related Terms


Bicara Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics PB Ratio Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
PB Ratio
0.00 0.00 1.93 2.37

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.55 1.16 2.14 2.37 2.54

BCAX vs ZYME, SRPT, INVA: PB Ratio Comparison

For the Biotechnology subindustry, Bicara Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bicara Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's PB Ratio falls into.


BCAX
12GF Score
Bicara Therapeutics Inc BCAX
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Bicara Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=28.37/7.841
=3.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 3.62 mean?
Bicara Therapeutics (BCAX) has a PB Ratio of 3.62 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bicara Therapeutics and its competitors. According to the industry distribution chart, Bicara Therapeutics ranks #711 out of 1232 companies in the Biotechnology industry, placing it in the top 57.7%.
Is Bicara Therapeutics' PB Ratio too high?
Bicara Therapeutics' current PB Ratio is 3.62. The Biotechnology industry median PB Ratio is 2.84. Bicara Therapeutics' value of 3.62 is 27.7% above this industry median. Based on the distribution chart, Bicara Therapeutics ranks #711 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' PB Ratio compare to ZYME and SRPT?
According to the Biotechnology industry distribution chart, Bicara Therapeutics ranks #711 out of 1232 companies for PB Ratio. This places Bicara Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.84. Bicara Therapeutics' value of 3.62 is 27.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.84, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bicara Therapeutics's current PB Ratio of 3.62 is 27.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bicara Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicara Therapeutics's current PB Ratio is 3.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current PB Ratio of 3.62. The current PB Ratio is 3.62 and 27.7% above the Biotechnology industry median of 2.84. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current PB Ratio is 3.62 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score

Get the complete analysis for BCAX

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.37
Price